

Clinical trials for Prima BioMed's CVac™ extended

24 April 2014 | News | By BioSpectrum Bureau



Singapore: Prima BioMed, Australia's leading biotechnology company pioneering in therapeutic area of cancer is said to be extending clinical trials of CVac™.

On Monday, the company is said to have made the decision to extend the clinical trials of CVac™, which is its flagship product candidate

The company's shares are in a trading halt, pending the announcement that is said to be made on June 26, Wednesday.